Evolution Wealth Advisors LLC Has $276,000 Position in Johnson & Johnson (NYSE:JNJ)

Evolution Wealth Advisors LLC boosted its holdings in Johnson & Johnson (NYSE:JNJ) by 118.8% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,855 shares of the company’s stock after buying an additional 1,007 shares during the period. Evolution Wealth Advisors LLC’s holdings in Johnson & Johnson were worth $276,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in JNJ. Winslow Evans & Crocker Inc. lifted its position in Johnson & Johnson by 0.3% during the second quarter. Winslow Evans & Crocker Inc. now owns 21,603 shares of the company’s stock valued at $3,037,000 after buying an additional 69 shares during the period. Lathrop Investment Management Corp increased its holdings in shares of Johnson & Johnson by 1.4% during the second quarter. Lathrop Investment Management Corp now owns 4,901 shares of the company’s stock valued at $689,000 after acquiring an additional 69 shares in the last quarter. Reik & CO. LLC increased its holdings in shares of Johnson & Johnson by 0.4% during the second quarter. Reik & CO. LLC now owns 17,727 shares of the company’s stock valued at $2,493,000 after acquiring an additional 70 shares in the last quarter. Old North State Trust LLC increased its holdings in shares of Johnson & Johnson by 0.5% during the second quarter. Old North State Trust LLC now owns 13,666 shares of the company’s stock valued at $1,922,000 after acquiring an additional 71 shares in the last quarter. Finally, Delta Investment Management LLC increased its holdings in shares of Johnson & Johnson by 1.0% during the second quarter. Delta Investment Management LLC now owns 7,406 shares of the company’s stock valued at $1,041,000 after acquiring an additional 71 shares in the last quarter. Institutional investors and hedge funds own 67.44% of the company’s stock.

In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 16,115 shares of the business’s stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $153.52, for a total transaction of $2,473,974.80. Following the completion of the sale, the executive vice president now directly owns 66,658 shares in the company, valued at approximately $10,233,336.16. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Ashley Mcevoy sold 29,000 shares of the business’s stock in a transaction dated Tuesday, July 28th. The shares were sold at an average price of $147.47, for a total value of $4,276,630.00. Following the sale, the executive vice president now owns 21,682 shares of the company’s stock, valued at $3,197,444.54. The disclosure for this sale can be found here. Insiders own 0.27% of the company’s stock.

NYSE JNJ opened at $148.10 on Friday. Johnson & Johnson has a one year low of $109.16 and a one year high of $157.00. The stock has a 50-day moving average of $148.57 and a 200 day moving average of $146.59. The company has a market capitalization of $389.92 billion, a price-to-earnings ratio of 23.29, a PEG ratio of 3.36 and a beta of 0.68. The company has a debt-to-equity ratio of 0.40, a quick ratio of 0.99 and a current ratio of 1.25.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Sunday, October 18th. The company reported $2.20 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.98 by $0.22. The business had revenue of $21.08 billion during the quarter, compared to the consensus estimate of $20.15 billion. Johnson & Johnson had a return on equity of 35.21% and a net margin of 22.69%. The business’s quarterly revenue was up 1.7% compared to the same quarter last year. During the same period in the previous year, the company posted $2.12 EPS. On average, equities analysts predict that Johnson & Johnson will post 8 earnings per share for the current fiscal year.

Several equities analysts have recently weighed in on the company. Bank of America restated a “buy” rating on shares of Johnson & Johnson in a report on Monday, July 20th. SVB Leerink restated an “outperform” rating on shares of Johnson & Johnson in a report on Wednesday, July 15th. Stifel Nicolaus downgraded Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Wednesday, August 19th. Citigroup raised their price target on Johnson & Johnson from $165.00 to $170.00 and gave the company a “buy” rating in a report on Friday, July 17th. Finally, Credit Suisse Group lifted their price objective on Johnson & Johnson from $163.00 to $168.00 and gave the stock an “outperform” rating in a report on Wednesday. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and ten have issued a buy rating to the company. Johnson & Johnson presently has a consensus rating of “Buy” and an average target price of $164.93.

Johnson & Johnson Company Profile

Johnson & Johnson researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Story: Commodities

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.